首页> 中文期刊> 《解放军医药杂志》 >喹硫平对社区慢性精神分裂症患者社会功能的康复疗效研究

喹硫平对社区慢性精神分裂症患者社会功能的康复疗效研究

             

摘要

Objective To investigate the effect of Quetiapine on social function in community patients with chro-nic schizophrenia. Methods Clinical data of 120 community patients with chronic schizophrenia during March 2010 and July 2013 was retrospectively analyzed, and the patients were divided into the observation group ( n=60 ) treated with Quetiapine, and the control group (n=60) treated with Perphenazine, and then the values of positive and negative syn-drome scale ( PANSS) , clinical effect, social disability screening schedule ( SDSS) score and incidence rate of adverse reaction in the two groups were compared. Results After the treatment, the total effective rate in the observation group (90. 00%) was significantly higher than that in control group (P<0. 05), while the scores of PANSS and SDSS in ob-servation group were significantly lower than those in the control group ( P<0. 05 ) . Conclusion Quetiapine in treat-ment of community patients with chronic schizophrenia can effectively improve the clinical symptoms, the social function and the quality of life with better prognosis.%目的 探讨喹硫平对社区慢性精神分裂症患者的临床疗效及社会功能的影响. 方法 回顾性分析我院2010年3月—2013年7月收治的120例社区慢性精神分裂症患者的临床资料,根据治疗方法的不同分为观察组和对照组,其中,观察组60例患者采用喹硫平治疗,而对照组60例患者采用奋乃静治疗,比较两组患者的PANSS量表评分、临床疗效、SDSS评分和不良反应. 结果 治疗后,观察组患者的总有效率为90. 00%,高于对照组患者( P<0. 05),观察组患者的PANSS评分和SDSS评分低于对照组(P<0. 05). 结论 采用喹硫平治疗社区慢性精神分裂症具有十分重要的作用,可有效改善患者的临床症状,提高患者的社会功能,改善患者的生活质量,促进患者的预后恢复.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号